Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14735881 | 0.82 | HCAR3 (0.57) | HCAR3TSHRCASP6MEN1KMT2A | |
| SCHEMBL6560128 | 0.82 | HCAR3 (0.57) | HCAR3TSHRCASP6MEN1KMT2A | |
| SCHEMBL6560146 | 0.82 | HCAR3 (0.57) | HCAR3TSHRCASP6MEN1KMT2A | |
| SCHEMBL6560138 | 0.82 | HCAR3 (0.57) | HCAR3TSHRCASP6MEN1KMT2A | |
| SCHEMBL4512467 | 0.82 | POLB (0.57) | TSHRMEN1KMT2ALMNAMAPT | |
| SCHEMBL6682207 | 0.81 | ALDH1A1 (0.52) | TSHRMEN1KMT2AMAPT | |
| SCHEMBL29276459 | 0.81 | HCAR3 (0.52) | HCAR3TSHRCASP6MEN1KMT2A | |
| SCHEMBL2441134 | 0.80 | MAPT (0.41) | TSHRLMNAMAPTPPARGPPARA | |
| SCHEMBL31733813 | 0.80 | MAPT (0.41) | TSHRLMNAMAPTPPARGPPARA | |
| SCHEMBL6559021 | 0.80 | ATM (0.49) | HCAR3MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| CN-101287707-A | Kinase inhibitors | DEVGEN NV (BE) | 2008-10-15 | — | — | CN | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | HCAR3 996/4885TSHR 1584/4885CASP6 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.